Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.
Accepted 2026-04-01 09:31:21 ET · period of report 2026-03-31 · accession 0001999371-26-007447 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-04-01 09:31 | 2026-03-31 | TNXP | LEDERMAN SETH | CEO, Dir | P - Purchase | $12.62 | +5,000 | 20.0K | +33% | +$63.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2026-03-31 | P | A | 5,000 | $12.62 | 20,001 | I By IRA Account | — | — | (F1) Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.5699 to $12.625 per share. The Reporting Persons undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. (F2) Reporting person may be deemed a control person of this entity. |